Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
← catalyst calendarNCT06084481 · readout ≤ 407 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
302actual
Sites
54
Countries
Australia, Israel, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-09 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hepatocellular Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Biliary Tract Cancers
- Esophageal Squamous Cell Carcinoma
- Triple Negative Breast Cancer
- Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Head and Neck Squamous-Cell Carcinoma
- Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions
- Drug: ABBV-400
- Drug: Itraconazole (ITZ)
- Drug: Bevacizumab
Primary outcomes
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured Up to 36 Months
Number of Participants with Adverse Events (AEs)
measured Up to 36 Months
Maximum Observed Concentration (Cmax) of ABBV-400 Conjugate
measured Up to 36 Months
AUC from Time 0 to the End of Dosing Interval (AUCtau) of ABBV-400 Conjugate
measured Up to 36 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed